Related Experiment Videos

Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug

T-C Hsia1, C-C Lin, J-J Wang

  • 1Division of Pulmonary/Critical Care Medicine, China Medical College Hospital, Taichung, Taiwan.

Lung
|August 15, 2002
PubMed

Insights

Detecting P-glycoprotein (Pgp) and multidrug resistance-related protein (MRP) expression in small cell lung cancer (SCLC) can predict chemotherapy response. Negative expression indicates a good response, while positive expression suggests poor outcomes.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Small cell lung cancer (SCLC) frequently develops resistance to chemotherapy, a significant clinical challenge.
  • The Multidrug Resistance 1 (MDR1) gene and multidrug resistance-related protein (MRP) gene are implicated in SCLC drug resistance.

Purpose of the Study:

  • To investigate the correlation between P-glycoprotein (Pgp) and MRP expression and chemotherapy response in SCLC patients.
  • To determine if Pgp or MRP expression can predict treatment outcomes in SCLC.

Main Methods:

  • Retrospective analysis of 50 SCLC patients' biopsy specimens.
  • Immunohistochemical detection of Pgp and MRP expression prior to chemotherapy.
  • Clinical and radiological evaluation of chemotherapy response after three months.

Main Results:

  • All 27 patients with a good chemotherapy response showed negative Pgp and MRP expression.
  • Among 23 patients with a poor response, varying combinations of positive Pgp and/or MRP expression were observed.
  • Positive Pgp and MRP expression was associated with poor chemotherapy response in SCLC.

Conclusions:

  • Immunohistochemical analysis of Pgp and MRP expression may serve as a predictive tool for chemotherapy response in SCLC.
  • Identifying patients with negative Pgp/MRP expression could guide treatment strategies for better outcomes.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...